One To Watch

Corlieve Therapeutics

Company Overview

A French gene therapy biotech founded in 2019 to develop miRNA-based AAV treatments for refractory temporal lobe epilepsy, acquired by uniQure in 2021 and now advancing its lead asset AMT-260 into Phase I/IIa clinical trials. Corlieve Therapeutics SAS was built around a single, sharply defined hypothesis: that silencing the GRIK2 gene in hippocampal neurons could break the seizure cycle in patients for whom antiseizure medications have already failed. The company was acquired by uniQure N.V. in July 2021 and continues to operate as a wholly-owned subsidiary, serving as the French operational base for uniQure's neurological gene therapy programs.

Headquarters and Global Presence

Corlieve Therapeutics SAS maintains operations across Paris and Bordeaux, France, reflecting its origins in French academic neuroscience. As a subsidiary of uniQure N.V. — headquartered in Lexington, Massachusetts, with manufacturing capabilities in the Netherlands — Corlieve benefits from a transatlantic development and manufacturing infrastructure.

Founding and History

Corlieve was founded in 2019 as a privately held French biotech to translate academic research on kainate receptor biology into a viable gene therapy for epilepsy. Its life as an independent company was brief but purposeful: uniQure announced its intention to acquire Corlieve on June 22, 2021, completing the transaction on July 30, 2021. The acquisition brought Corlieve's lead miRNA program — now designated AMT-260 — into uniQure's neurological pipeline, where it has since progressed to first-in-human dosing. Corlieve was not dissolved; it remains an active legal entity and operational subsidiary.

Therapy Areas and Focus

Corlieve's sole focus is refractory mesial temporal lobe epilepsy (MTLE), the most common form of drug-resistant focal epilepsy and one where surgical resection — the current last resort — carries significant cognitive risk and is unsuitable for many patients. Approximately one-third of epilepsy patients do not achieve adequate seizure control on medication, and MTLE accounts for a disproportionate share of that population. A one-time gene therapy that could durably suppress seizure activity in the hippocampus without the morbidity of open surgery addresses a genuine and poorly served clinical need.

Technology Platforms and Modalities

AMT-260 uses an adeno-associated virus (AAV) vector to deliver an artificial microRNA (miRNA) sequence designed to suppress expression of the GRIK2 gene, which encodes the GluK2 kainate receptor subunit. Kainate receptors are concentrated in hippocampal circuits and are implicated in the pathological hyperexcitability that drives MTLE seizures. By downregulating GluK2 expression locally rather than broadly antagonizing the receptor pharmacologically, the approach aims for durable, region-specific seizure suppression from a single stereotactic administration. This silencing strategy — a gene therapy that turns down a target rather than replacing a missing gene — is mechanistically distinct from most gene therapies in the neurological space, which predominantly focus on enzyme replacement or loss-of-function correction.

Key Pipeline and Programs

AMT-260 is Corlieve's originating asset and uniQure's lead neurological program. It is an AAV-delivered miRNA targeting GRIK2/GluK2, administered as a one-time stereotactic hippocampal injection in adults with unilateral refractory MTLE. The GenTLE study (NCT06063850) is an open-label, dose-escalation Phase I/IIa trial evaluating two dose levels, with no placebo arm, in adults whose seizures have persisted despite multiple antiseizure medications. The study is currently enrolling and has dosed its first patient, with the primary objectives being safety, tolerability, and early efficacy signals. Early data presented in May 2025 from the first dosed patient showed a 92% reduction in seizure frequency over five months, with no seizures reported in the final 60 days of observation and no serious adverse events — a single-patient, uncontrolled signal, but one striking enough to validate the target and delivery approach. No additional Corlieve-originated programs beyond AMT-260 are disclosed in the current pipeline.

Recent Developments

On May 29, 2025, uniQure presented a clinical case study at a scientific meeting reporting that the first patient dosed with AMT-260 in the GenTLE trial achieved a 92% reduction in seizure frequency over five months post-treatment, with a seizure-free period of 60 days and a clean safety profile to date. The data are early and drawn from a single patient in an open-label study, so firm efficacy conclusions are premature — but the magnitude of the seizure reduction and the absence of serious adverse events have strengthened confidence in the GRIK2 silencing hypothesis. Enrollment in the Phase I/IIa dose-escalation trial continues, with the study evaluating two dose levels.

Key Personnel

Matt Kapusta serves as Chief Executive Officer of uniQure, the parent company overseeing AMT-260's clinical development; he has led uniQure through its pivot toward a neurological gene therapy portfolio following the hemophilia B program's commercial transition to CSL Behring. Corlieve's founding scientific leadership drew on expertise in kainate receptor neurobiology developed within the French academic research system, underpinning the mechanistic rationale for GRIK2 silencing as an epilepsy target.

Strategic Partnerships

Corlieve's defining strategic event was its acquisition by uniQure N.V., completed July 30, 2021, which provided the manufacturing scale, AAV vector expertise, and clinical development infrastructure that a 2019-vintage French biotech could not have assembled independently. Operating within uniQure, the AMT-260 program benefits from the parent company's established AAV production capabilities in the Netherlands and its existing regulatory relationships with the FDA and EMA. No separate licensing or co-development partnerships for the Corlieve program have been disclosed.

FAQ Section

Corlieve offered uniQure a ready-made scientific rationale — GRIK2-targeted miRNA silencing — grounded in years of academic kainate receptor research in France, alongside a lead asset that could be rapidly transitioned into uniQure's AAV manufacturing platform. Acquiring a focused, single-asset biotech at an early stage is considerably cheaper than building a de novo CNS program, and it gave uniQure a credible neurological pipeline anchor as the company sought to diversify beyond hemophilia. The deal, announced June 2021 and closed within six weeks, reflects how quickly uniQure moved when it identified the asset.

GluK2-containing kainate receptors are densely expressed in CA3 hippocampal neurons — precisely the circuits implicated in MTLE seizure generation — making them an anatomically logical target for focal intervention. Unlike AMPA or NMDA receptors, kainate receptors have a narrower distribution in the brain, so suppressing GluK2 expression locally carries a better therapeutic index than broad glutamate receptor antagonism, which historically has produced intolerable CNS side effects. The miRNA approach delivers sustained gene silencing from a single dose, avoiding the compliance issues and fluctuating drug levels inherent in chronic antiseizure medication regimens.

Most neurological gene therapies aim to restore a missing or defective protein — a straightforward enzyme or structural gene replacement strategy. AMT-260 takes a gene silencing approach, using an artificial miRNA to downregulate an endogenous, disease-relevant receptor subunit, which is mechanistically closer to RNA interference therapeutics than to classical gene replacement. The hippocampal-specific delivery via stereotactic injection also distinguishes AMT-260 from systemic or intrathecal approaches: the goal is local circuit modulation, not broad CNS transduction. This specificity is both the scientific strength of the program and the practical constraint that limits it to unilateral MTLE.

The single patient dosed in the GenTLE trial (NCT06063850) showed a 92% reduction in seizure frequency over five months, including a 60-day seizure-free window, with no serious adverse events reported as of May 2025. Those numbers are striking — but this is one patient, in an open-label study with no control arm, observed over a relatively short post-dosing window. The GenTLE design is explicitly a Phase I/IIa safety and dose-finding study; the efficacy signal is hypothesis-generating, not confirmatory. The relevant question is whether this pattern holds across the cohort at both dose levels and over longer follow-up.

AMT-260 targets adults with unilateral refractory MTLE — patients who have failed multiple antiseizure medications and whose seizures originate from one hippocampus. Temporal lobe epilepsy is the most prevalent form of focal epilepsy, and roughly one-third of epilepsy patients are medication-refractory; MTLE accounts for a substantial proportion of that group. Current alternatives for this population are limited to temporal lobectomy or laser ablation, both of which carry neurocognitive risk and are unsuitable for some patients anatomically or by preference — defining a commercially addressable unmet need even if absolute patient numbers are modest.

AMT-260 is in Phase I/IIa development, with the GenTLE trial (NCT06063850) actively enrolling and the first patient dosed. The study is evaluating two dose levels in an open-label, dose-escalation design, meaning safety and tolerability at each dose level must be established before the higher dose cohort opens. The immediate milestones are safety data across the full Phase I/IIa cohort and, critically, durability of seizure suppression beyond the initial five-month window reported for patient one. Any move toward a controlled Phase IIb/III study is contingent on those readouts.

The program's trajectory over the next 12-24 months will be shaped by several converging factors:

Cohort-level GenTLE data: whether the 92% seizure reduction seen in patient one replicates across additional patients at both dose levels, and whether the effect is durable beyond six months.
Safety profile at the higher dose: stereotactic hippocampal injection carries procedural risk, and any serious adverse events at dose escalation would materially set back the program.
uniQure's broader portfolio priorities: AMT-260 competes for resources against uniQure's Huntington's disease program (AMT-130), which is further advanced; a strategic pivot or resource constraint at the parent level could slow Corlieve's program.
Regulatory interactions: FDA and EMA feedback on the Phase I/IIa design will shape whether a controlled pivotal study is feasible without further proof-of-concept work.
Competitive landscape: no approved gene therapy for epilepsy exists, but academic and commercial programs targeting SCN1A (Dravet syndrome) and other epilepsy genes are advancing, raising the bar for what counts as a differentiated approach.

Want to Update your Company's Profile?